Drug name - Caplyta

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9586960 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Mar, 2029

(6 years from now)

USRE48825 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Mar, 2029

(6 years from now)

US8648077 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Dec, 2029

(7 years from now)

CN102046175A INTRA-CELLULAR Substituted Heterocycle Fused Gamma-Carbolines Solid
Mar, 2029

(6 years from now)

CN102046175B INTRA-CELLULAR A Heterocyclic Ring Fused Gamma-Carbolines Solid
Mar, 2029

(6 years from now)

EP2262505B1 INTRA-CELLULAR Substituted Heterocycle Fused Gamma-Carbolines Solid
Mar, 2029

(6 years from now)

EP2262505A2 INTRA-CELLULAR Substituted Heterocycle Fused Gamma-Carbolines Solid
Mar, 2029

(6 years from now)

EP2262505A4 INTRA-CELLULAR Substituted Heterocycle Fused Gamma-Carbolines Solid
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464938 INTRA-CELLULAR Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof Mar, 2028

(5 years from now)

US9199995 INTRA-CELLULAR 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals Mar, 2029

(6 years from now)

US10117867 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders May, 2029

(6 years from now)

US9616061 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders May, 2029

(6 years from now)

USRE48839 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders Dec, 2029

(7 years from now)

US8598119 INTRA-CELLULAR Methods and compositions for sleep disorders and other disorders Dec, 2029

(7 years from now)

US10960009 INTRA-CELLULAR Methods of treating schizophrenia and depression Dec, 2034

(12 years from now)

US11026951 INTRA-CELLULAR Methods of treating bipolar disorder Dec, 2034

(12 years from now)

US9956227 INTRA-CELLULAR Method for the treatment of residual symptoms of schizophrenia Dec, 2034

(12 years from now)

US10695345 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Aug, 2039

(16 years from now)

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of bipolar depression; treatment of schizophrenia; Treatment of schizophrenia; Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia with improvement in residual symptoms of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 42MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.